Aprea Therapeutics, Inc. Accounts Payable
Aprea Therapeutics, Inc. (APRE) had Accounts Payable of $935.14 thousand as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-12
- 2026-06-30: Accounts Payable, Current $935.14K.
- 2026-03-31: Accounts Payable, Current $2.94M.
- 2025-12-31: Accounts Payable, Current $713.67K.
- 2025-09-30: Accounts Payable, Current $641.32K.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $935.14K 10-Q · filed 2026-08-12 |
| 2026-03-31 | $2.94M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $713.67K 10-Q · filed 2026-08-12 |
| 2025-09-30 | $641.32K 10-Q · filed 2025-11-12 |
| 2025-06-30 | $1.20M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $1.28M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $1.35M 10-K · filed 2026-03-16 |
| 2024-09-30 | $1.15M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $964.33K 10-Q · filed 2024-08-12 |
| 2024-03-31 | $1.32M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $1.67M 10-K · filed 2025-03-25 |
| 2023-09-30 | $862.55K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $1.13M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $826.03K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $842.75K 10-K · filed 2024-03-26 |
| 2022-09-30 | $1.14M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $3.99M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $1.99M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $1.77M 10-K · filed 2023-03-30 |
| 2021-09-30 | $2.55M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $2.36M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $3.46M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $4.50M 10-K · filed 2022-03-15 |
| 2020-09-30 | $4.35M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $5.44M 10-Q · filed 2020-08-11 |
| 2020-03-31 | $3.01M 10-Q · filed 2020-05-15 |
| 2019-12-31 | $2.18M 10-K · filed 2021-03-16 |
| 2019-09-30 | $3.51M 10-Q · filed 2019-11-14 |
| 2018-12-31 | $1.74M 10-K · filed 2020-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |